Novel Etomidate Derivatives

Author(s): J. Robert Sneyd

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 38 , 2012

Become EABM
Become Reviewer
Call for Editor


Etomidate is a well established intravenous anaesthetic agent which has been widely used. Recognised limitations of the agent include adrenocortical suppression, myoclonus and post-operative nausea and vomiting, PONV. MOC-etomidate, carboetomidate and MOC-carboetomidate are novel etomidate derivatives. Their preclinical data and their potential for human administration are critically reviewed. ‘Soft’ pharmacology (rapid ester hydrolysis) limits the duration of action of MOC-etomidate and MOC-carboetomidate giving them rapid offset after administration is discontinued. Adrenocortical depression is minimised either by ester hydrolysis or by structural change to the etomidate molecule. Potential limitations include the yet to be determined incidence of myoclonus and PONV if these new agents are administered to humans.

Keywords: Etomidate, MOC-etomidate, carboetomidate, MOC-carboetomidate, propofol, midazolam

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 29 October, 2012
Page: [6253 - 6256]
Pages: 4
DOI: 10.2174/138161212803832362
Price: $65

Article Metrics

PDF: 12